Uncategorized
Iluvien receives marketing approval in Denmark for chronic DME
The Danish Health and Medicines Authority has granted marketing approval of Iluvien for the treatment of vision impairment associated with chronic diabetic macular edema, according to an Alimera press release.Denmark is the second country to grant national marketing authorization for Iluvien (190 mcg intravitreal implant in applicator, Alimera). The U.S. Food and Drug Administration is currently reviewing the company’s new drug application.